IRONWOOD PHARMACEUTICALS, INC. Defined Contribution Plan, Cost
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Defined Contribution Plan, Cost of $1.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2025 was $1.20M, a 50.00% decline from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2024 was $2.40M, a 9.09% increase from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2023 was $2.20M, a 0.00% change from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2022 was $2.20M, a 0.00% change from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.20M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $2.40M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $2.20M 10-K · filed 2025-03-31 | |
| 2022-12-31 | $2.20M 10-K · filed 2025-03-31 | |
| 2021-12-31 | $2.20M 10-K · filed 2024-02-16 | |
| 2020-12-31 | $1.80M 10-K · filed 2023-02-16 | |
| 2019-12-31 | $2.20M 10-K · filed 2022-02-18 | |
| 2018-12-31 | $3.20M 10-K · filed 2021-02-17 | $3.70M 10-K · filed 2019-02-25 |
| 2017-12-31 | $3.50M 10-K · filed 2020-02-13 | $3.90M 10-K · filed 2018-02-22 |
| 2016-12-31 | $3.20M 10-K · filed 2019-02-25 | |
| 2015-12-31 | $2.50M 10-K · filed 2018-02-22 | |
| 2014-12-31 | $2.60M 10-K · filed 2017-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |